Predictors of quetiapine extended release formulation Add-On in older patients exposed to antidepressant drugs: A Danish Register-Based cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Predictors of quetiapine extended release formulation Add-On in older patients exposed to antidepressant drugs : A Danish Register-Based cohort study. / Hashimi, Hadia; Andersen, Morten; Sessa, Maurizio.
In: International Journal of Geriatric Psychiatry, Vol. 35, No. 10, 2020, p. 1156-1162.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predictors of quetiapine extended release formulation Add-On in older patients exposed to antidepressant drugs
T2 - A Danish Register-Based cohort study
AU - Hashimi, Hadia
AU - Andersen, Morten
AU - Sessa, Maurizio
N1 - This article is protected by copyright. All rights reserved.
PY - 2020
Y1 - 2020
N2 - OBJECTIVE: This study investigated which comorbidities or comedications increased the probability of receiving quetiapine extended release formulation (quetiapine XR) as an add-on treatment.METHODS: Danish administrative registers were used as data sources. The study period was from January 1, 2011 to July 1, 2017. New users of Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin and Norepinephrine Reuptake Inhibitors (SNRI), Atypical Antidepressants (AAD) and Tricyclic Antidepressants (TCA) aged ≥65 years were included in the study population. A multivariable Cox regression model was used to find predictors for receiving quetiapine XR add-on within the first year of antidepressant therapy.RESULTS: 123 655 new users of SSRI, SNRI, TCA and AAD were eligible. The study population was composed of 57.7% females and the mean age was 77.2 years (SD 7.9 years). SSRIs users comprised 49.6% of the study population. Among users of antidepressants, 171 (0.14%) patients received quetiapine XR as add-on treatment. In the adjusted analyses, female patients (HR 0.70; 95%CI 0.52-0.95) and glucocorticoid users (HR 0.41; 95%CI 0.21-0.80) had a significantly lower hazard of receiving quetiapine XR. Patients with dementia (HR 2.43; 95%CI 1.52-3.87) had a significantly higher hazard of receiving quetiapine XR than patients without this condition. When compared to SSRI users, AAD (HR 1.80; 95%CI 1.31-2.46) and TCA users (HR 0.18; 95%CI 0.06-0.49) had an increased/reduced hazard of receiving quetiapine XR, respectively.CONCLUSIONS: This study suggests that the choice of prescribing quetiapine add-on is driven by patient's differences in comorbidities, comedications and the type of antidepressant drug.
AB - OBJECTIVE: This study investigated which comorbidities or comedications increased the probability of receiving quetiapine extended release formulation (quetiapine XR) as an add-on treatment.METHODS: Danish administrative registers were used as data sources. The study period was from January 1, 2011 to July 1, 2017. New users of Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin and Norepinephrine Reuptake Inhibitors (SNRI), Atypical Antidepressants (AAD) and Tricyclic Antidepressants (TCA) aged ≥65 years were included in the study population. A multivariable Cox regression model was used to find predictors for receiving quetiapine XR add-on within the first year of antidepressant therapy.RESULTS: 123 655 new users of SSRI, SNRI, TCA and AAD were eligible. The study population was composed of 57.7% females and the mean age was 77.2 years (SD 7.9 years). SSRIs users comprised 49.6% of the study population. Among users of antidepressants, 171 (0.14%) patients received quetiapine XR as add-on treatment. In the adjusted analyses, female patients (HR 0.70; 95%CI 0.52-0.95) and glucocorticoid users (HR 0.41; 95%CI 0.21-0.80) had a significantly lower hazard of receiving quetiapine XR. Patients with dementia (HR 2.43; 95%CI 1.52-3.87) had a significantly higher hazard of receiving quetiapine XR than patients without this condition. When compared to SSRI users, AAD (HR 1.80; 95%CI 1.31-2.46) and TCA users (HR 0.18; 95%CI 0.06-0.49) had an increased/reduced hazard of receiving quetiapine XR, respectively.CONCLUSIONS: This study suggests that the choice of prescribing quetiapine add-on is driven by patient's differences in comorbidities, comedications and the type of antidepressant drug.
U2 - 10.1002/gps.5351
DO - 10.1002/gps.5351
M3 - Journal article
C2 - 32428273
VL - 35
SP - 1156
EP - 1162
JO - International Journal of Geriatric Psychiatry
JF - International Journal of Geriatric Psychiatry
SN - 0885-6230
IS - 10
ER -
ID: 242774314